{
  "timestamp": "20250104_061124",
  "model": "gpt-4-turbo",
  "interaction_type": "answer_with_CoT",
  "question_id": "41b7270c",
  "question_text": "Gp2b3A inhibitors are all except -",
  "messages": [
    {
      "role": "system",
      "content": "You are a medical expert using chain-of-thought reasoning."
    },
    {
      "role": "user",
      "content": "You are a medical expert specializing in the field of Pharmacology.\n            You are a medical expert determining the final answer.\n\n                ### Instructions:\n                - Use standard medical knowledge as the primary guide.\n                - Consider enhanced information only if it aligns with consensus.\n                - If conflicting or unclear, present the most likely correct answer based on known facts.\n                - It's acceptable to show moderate confidence if the question is complex, but still choose one best answer.\n            ### Question    \n            Gp2b3A inhibitors are all except -\n\n            ### Options\n            opa. Abciximab\nopb. Eptifibatide\nopc. Tirofiban\nopd. Prasugrel\n\n### Reasoning Chains for Validation:\n- CHAIN: \"Abciximab\" -> \"Gp2b3A inhibitor\" -> 95% CHAIN: \"Eptifibatide\" -> \"Gp2b3A inhibitor\" -> 95% CHAIN: \"Tirofiban\" -> \"Gp2b3A inhibitor\" -> 95% CHAIN: \"Prasugrel\" -> \"Not a Gp2b3A inhibitor\" -> \"Thienopyridine class\" -> \"Inhibits platelet activation by blocking ADP receptors\" -> 95%\n\n### Retrieved Validation Paths:\n- (thienopyridine)-TREATS->(Kidney Failure, Chronic)-INTERACTS_WITH->(Virus)-LOCATION_OF->(Liposomes)-LOCATION_OF->(Medical Imaging)-DIAGNOSES->(Mental blocking)\n\n            ### Task:\n                1. Identify the core medical principle and the most likely correct option based on consensus.\n                2. If the evidence is not perfectly clear, pick the best-supported option and explain the reasoning.\n                3. Provide a final analysis and a confidence score (0-100%).\n                \n                ### Output Format:\n                {\n                  \"final_analysis\": \"Step-by-step reasoning, prioritizing medical consensus and acknowledging complexity if present.\",\n                  \"answer\": \"Option key (e.g. opa, opb, ...)\",\n                  \"confidence\": A number between 0-100\n                }\n            "
    }
  ],
  "response": "### Core Medical Principle:\nGp2b3A inhibitors are a class of antiplatelet drugs that prevent platelet aggregation by blocking the glycoprotein IIb/IIIa receptor on the surface of platelets. This action is crucial in the management of acute coronary syndromes and during percutaneous coronary interventions.\n\n### Analysis of Options:\n- **Abciximab (opa)**: It is a well-known Gp2b3A inhibitor, used to prevent platelets from sticking together and forming blood clots.\n- **Eptifibatide (opb)**: This is also a Gp2b3A inhibitor. It works similarly to Abciximab by blocking the glycoprotein IIb/IIIa receptor.\n- **Tirofiban (opc)**: Tirofiban is another drug in the same class, inhibiting the Gp2b3A receptor to reduce the risk of forming clots.\n- **Prasugrel (opd)**: Prasugrel is not a Gp2b3A inhibitor. It belongs to the thienopyridine class and works by inhibiting platelet activation through a different mechanism, specifically by blocking ADP receptors.\n\n### Final Analysis:\nBased on the standard medical knowledge, Abciximab, Eptifibatide, and Tirofiban are confirmed Gp2b3A inhibitors. Prasugrel, however, operates through a different mechanism by targeting ADP receptors and not the Gp2b3A receptor. Therefore, it does not belong to the Gp2b3A inhibitor class.\n\nGiven the clear differentiation in the mechanism of action between Prasugrel and the other options, and the consensus in medical literature regarding the classification of these drugs, the answer is confidently identified.\n\n```json\n{\n  \"final_analysis\": \"Abciximab, Eptifibatide, and Tirofiban are Gp2b3A inhibitors, confirmed by their mechanism of action in inhibiting the glycoprotein IIb/IIIa receptor. Prasugrel, however, acts by inhibiting ADP receptors, not Gp2b3A, and is therefore not a Gp2b3A inhibitor. This conclusion aligns with standard pharmacological classifications.\",\n  \"answer\": \"opd\",\n  \"confidence\": 95\n}\n```",
  "metadata": {
    "topic": "Pharmacology",
    "is_multi_choice": true,
    "has_reasoning_chain": true,
    "has_enhanced_info": true,
    "model_config": "gpt-4-turbo",
    "temperature": 0.0
  }
}